Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy

Keith W. Crawford, Dorothy Njeru, Jonah Maswai, Milton Omondi, Duncan Apollo, Jane Kimetto, Lawrence Gitonga, James Munyao, Raphael Langat, Appolonia Aoko, Jemutai Tarus, Samoel Khamadi, Tiffany E. Hamm

Research output: Contribution to journalArticlepeer-review

Abstract

Resistance to efavirenz and nevirapine has not been associated withmutations at position 138 of reverse transcriptase. In an evaluation of virologic suppression rates in PEPFAR (President's Emergency Plan For AIDS Relief) clinics in Kenya among patients on first-line therapy (RV288), 63% (617/975) of randomly selected patients on antiretroviral therapy were suppressed (HIV RNA<400 copies/ml). Among those with non-nucleoside reverse transcriptase inhibitor resistance (n=101), 14 (13.8%) had substitutions at 138 (A, G, K or Q), mutations selected only by etravirine and rilpivirine in subtype B viruses. All 14 patients received efavirenz or nevirapine, not etravirine or rilpivirine, and were predominantly subtype A1. This may be the first report of efavirenz and nevirapine selecting these mutations in these subtypes.

Original languageEnglish (US)
Pages (from-to)442-445
Number of pages4
JournalAIDS
Volume28
Issue number3
DOIs
StatePublished - Jan 28 2014

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy'. Together they form a unique fingerprint.

Cite this